SCHEMBL5939367

SCHEMBL5939367

C1=CC[C@@H]2NCCC[C@H]2C1

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EPAS1 Q99814 1/20 0.38
MBTD1 Q05BQ5 1/20 0.33
L3MBTL3 Q96JM7 1/20 0.33
HRH4 Q9H3N8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5939649 1.00 EPAS1 (0.38) EPAS1MBTD1L3MBTL3HRH4
SCHEMBL5939656 1.00 EPAS1 (0.38) EPAS1MBTD1L3MBTL3HRH4
SCHEMBL5939379 1.00 EPAS1 (0.38) EPAS1MBTD1L3MBTL3HRH4
SCHEMBL3357590 0.84
SCHEMBL3357588 0.84
SCHEMBL3357586 0.84
SCHEMBL790752 0.81 EPAS1 (0.36) EPAS1MBTD1L3MBTL3HRH4
SCHEMBL13200281 0.78
SCHEMBL21722574 0.76 EPAS1 (0.36) EPAS1MBTD1L3MBTL3HRH4
SCHEMBL2292798 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4540787-A Method of preparing trans-D1-1-alkyl-6-oxodecahydroquinolines ELI LILLY AND COMPANY (US) 1985-09-10 US claimed
US-20060287290-A1 Azabicyclic compounds are central nervous system active agents DART MICHAEL J 2006-12-21 US disclosed
US-7135484-B2 Azabicyclic compounds are central nervous system active agents ABBOTT LABORATORIES (US) 2006-11-14 US disclosed
US-20040152724-A1 Azabicyclic compounds are central nervous system active agents ABBVIE INC. 2004-08-05 US disclosed
US-20040044029-A1 Azabicyclic compounds are central nervous system active agents ABBOTT LABORATORIES 2004-03-04 US disclosed
US-5929087-A Decahydroquinoline-based anti-cholinergic agents REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1999-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152724-A1 Azabicyclic compounds are central nervous system active agents ACHE, CHRNA6, CHRNA2 EPAS1 3188/4885MBTD1 1366/4885L3MBTL3 4714/4885
US-20040044029-A1 Azabicyclic compounds are central nervous system active agents ACHE, CHRNA6, CHRNA2 EPAS1 3188/4885MBTD1 1366/4885L3MBTL3 4714/4885
US-20060287290-A1 Azabicyclic compounds are central nervous system active agents ACHE, CHAT, CHRNA6 EPAS1 3796/4885MBTD1 2596/4885L3MBTL3 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.